y-90 ibritumomab tiuxetan (zevalin)

Question 1

antibody directed against

Answer 1

NHL b lymphocytesadmin

Question 2

admin via

Answer 2

2 doses

Question 3

what are doses labeled with

Answer 3

In111 and used as confirmation for final therpay dose and therpay dose labeled with y90 bc beta emitter

Question 4

ibritumomba is a

Answer 4

murine antibody agaisnt antigen found on b lymphocytes that are normal and maligannat

Question 5

rituximab is same antibody as

Answer 5

ibritumomab and less linking and chelating parts. used alone for NHL

Question 6

y90 half life and energy

Answer 6

64.1 hours and beta of 750-935kev

Question 7

labeling of y-90 zevalin 4 components

Answer 7

-sodium acetate buffer
-isotope
-antibody
-formulation buffer

Question 8

dose of antibody for 5.0 mCi In 111 study is

Answer 8

1.6 mg

Question 9

dose of Ab for y90 therapy study is about

Answer 9

2.3 mg

Question 10

activity for y90 is based on

Answer 10

normal distribution of In 111 Ab determined by WB scan

Question 11

platelet 150,000

Answer 11

dose is 0.4 mCi/kg

Question 12

platelet between 150,000-100,000

Answer 12

dose 0.3 mCi/kg

Question 13

no admin witg levels below

Answer 13

100,000

Question 14

rituximab pre admin is

Answer 14

250mg/m2 of colf antibody before zevalin

Question 15

dose of zevalin admin as a 10 min infusion in a what filter size

Answer 15

0.22 microns

Question 16

final volume of zevlin dose

Answer 16

8-10 mL